AB0233 ONE YEAR RESPONSE AND ASSOCIATED FACTORS FOR REMISSION AND LOW ACTIVITY DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE MEXICAN BIOLOGICS REGISTRY
Authors: V. Rivera Teran, D. Vega-Morales, S. Sicsik, A. Castillo Ortiz, F. Irazoque-Palazuelos, D. Miranda, I. J. Colunga-Pedraza, J. C. Casasola, O. E. Muñoz-Monroy, S. Carrilo, A. Peña, S. Duran Barragan, L. F. Valdés Corona, E. Torres Valdéz, A. Ramos, A. Paz, E. A. Zamora-Tehozol, D. X. Xibille Friedmann, D. Alpizar-Rodriguez
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Rheumatoid arthritis (RA) is the most common autoimmune disease. Clinical remission is the main therapeutic target for patients with RA, with low disease activity (LDA) as a best possible alternative<sup>[1]</sup>. <h3>Objectives</h3> Evaluate clinical response of patients with RA treated with biologic (bDMARDs) and the associated factors for remission and low activity disease at the first year of treatment. <h3>Methods</h3> BIOBADAMEX is a Mexican ongoing cohort of patients using bDMARDs since 2016. In this analysis we included all patients with diagnosis of RA with at least two assessments, baseline and at one year of follow up. Clinical response was measured by DAS-28 score and factors associated with having a remission or low disease activity vs moderate/high activity were estimated using univariable and multivariable logistic regression analysis adjusting by potential confounders, such as age, gender, disease duration. <h3>Results</h3> A total of 336 RA patients were included in this analysis. At baseline 68 (20%) and after one year of follow 171 (50.1%) were in remission or low activity disease. Mean baseline disease duration was 8.8 years. Table 1 shows baseline characteristics by groups. Baseline steroid treatment and previous biologic treatment were the only factors associated with less probability of being in remission/low disease activity at one year in our cohort. In multivariable analysis adjusted by age, gender, disease duration, these two factors were no longer associated with remission/low disease activity (p=0.055 and p=0.14, respectively). <h3>Conclusion</h3> In our registry baseline steroid treatment and previous biologic treatment were the only factors associated with less probability of being in remission/low disease activity at one year on biologic treatment, however these factors did not remain significant associated after adjusted analysis. Follow up and inclusion of more participants is going on and will allow us to perform further analyses. <h3>Reference</h3> [1] Smolen JS et al. Ann Rheum Dis. 2020;79(6):685-699. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Vijaya Rivera Teran: None declared, David Vega-Morales: None declared, Sandra Sicsik: None declared, Angel Castillo Ortiz: None declared, Fedra Irazoque-Palazuelos: None declared, Dafhne Miranda: None declared, Iris Jazmin Colunga-Pedraza: None declared, Julio Cesar Casasola: None declared, Omar Eloy Muñoz-Monroy: None declared, Sandra Carrilo: None declared, Angélica Peña: None declared, Sergio Duran Barragan: None declared, Luis Francisco Valdés Corona: None declared, Estefanía Torres Valdéz: None declared, Azucena Ramos: None declared, Aleni Paz: None declared, ERICK ADRIAN ZAMORA-TEHOZOL: None declared, Daniel Xavier Xibille Friedmann: None declared, Deshire Alpizar-Rodriguez Employee of: Scientific advisor GSK-Mexico.